Beta · prototype— This site is under construction: rankings, texts and features change every week.

Qventus

Active#9 worldwide · Clinical software

Clinical software

HQUnited States
Last roundSeries D · Jan 2025

Uback rankings

How the AI ranks →
RankingTierRankEditionNext update
Clinical software · worldwideTop 14#9Edition 0 (beta) · Sep 202622 Feb 2027
Rank historySep 2026 · #9 Clinical softwareFirst edition: no movements yet.

Estimated valuation

AI · Clinical software ranking (worldwide)
≈ USD 550MUSD 370–820M · Hundreds of M$ Medium confidence
Anchor
Last known equity round: Series D · USD 105M · Jan 2025

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Funding history

DateRoundAmountTypeInvestorsSource
Jan 2025Series DUSD 105MEquityKKRqventus.com

Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Qventus as a PDF, on one of three angles only:

ValuationWhat is Qventus worth?
Versus competitorsHow does it compare?
Who should acquire itStrategic buyers, and why
Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.

Comparable companies in clinical software

Full clinical software ranking →

Investors in Qventus: KKR

Sources. qventus.com

Last updated: Sep 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.